- Home
- STAI vs LSTA Comparison
STAI vs LSTA Comparison
Compare STAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- LSTA
- Stock Information
- Founded
- STAI 2011
- LSTA 1980
- Country
- STAI United States
- LSTA United States
- Employees
- STAI N/A
- LSTA N/A
- Industry
- STAI
- LSTA Misc Health and Biotechnology Services
- Sector
- STAI
- LSTA Health Care
- Exchange
- STAI Nasdaq
- LSTA Nasdaq
- Market Cap
- STAI 24.6M
- LSTA 22.3M
- IPO Year
- STAI N/A
- LSTA N/A
- Fundamental
- Price
- STAI $0.45
- LSTA $2.39
- Analyst Decision
- STAI
- LSTA Strong Buy
- Analyst Count
- STAI 0
- LSTA 2
- Target Price
- STAI N/A
- LSTA $23.50
- AVG Volume (30 Days)
- STAI 2.3M
- LSTA 21.2K
- Earning Date
- STAI 09-17-2025
- LSTA 11-11-2025
- Dividend Yield
- STAI N/A
- LSTA N/A
- EPS Growth
- STAI N/A
- LSTA N/A
- EPS
- STAI N/A
- LSTA N/A
- Revenue
- STAI $907,637.00
- LSTA $1,070,000.00
- Revenue This Year
- STAI N/A
- LSTA N/A
- Revenue Next Year
- STAI N/A
- LSTA N/A
- P/E Ratio
- STAI N/A
- LSTA N/A
- Revenue Growth
- STAI N/A
- LSTA N/A
- 52 Week Low
- STAI $0.35
- LSTA $1.87
- 52 Week High
- STAI $9.07
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- STAI 48.15
- LSTA 51.61
- Support Level
- STAI $0.35
- LSTA $2.10
- Resistance Level
- STAI $0.50
- LSTA $2.43
- Average True Range (ATR)
- STAI 0.04
- LSTA 0.17
- MACD
- STAI 0.02
- LSTA 0.02
- Stochastic Oscillator
- STAI 64.29
- LSTA 82.05
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.